Crispin Hiley and Stephanie Saw
Mar 27, 2025, 13:04
Crispin Hiley: Stephanie Saw on Post-Osimertinib Decision Making in EGFR+ NSCLC
Crispin Hiley, UK Clinical Director for Lung Cancer at GenesisCare, shared a post on X:
“Slick discussion of complexity post Osimertinib decision making for patients with EGFR mutation positive NSCLC by Stephanie Saw – it’s a good problem to have in 2025.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 18:07
Jun 2, 2025, 18:00
Jun 2, 2025, 17:43
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20